Compounding refers to the science of producing tailored medications for providing personalized solutions to patients. Veterinarians can prescribe compounded medications for pets in various formulation types such as compounded tablets and chews, flavored suspensions, and transdermal medication.
Global Veterinary Drugs Compounding Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 256 million cases and 5.15 million deaths due to coronavirus (COVID-19) were reported till November 22, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Veterinary Drugs Compounding
The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
The impact of COVID-19 was sudden and varied across the veterinary drug industry. Considering the enforcement of lockdown in various regions the veterinary practices were hindered to a certain extent. For instance, according to the American Veterinary Medical Association, in April 2020, globally, around 60% of the veterinary practices were cancelled owing to the pandemic and in July 2020, the number of veterinary practices dropped to around 30%. Thus, the COVID-19 impact is expected to hamper the growth of global veterinary drugs compounding market.
The global veterinary drugs compounding market is estimated to be valued at US$ 1,179.7 Mn in 2021, and is expected to exhibit a CAGR of 5.5 % over the forecast period (2021-2028).
Figure 1: Global Veterinary Drugs Compounding Market Share (%) Analysis, By Drug Class, 2021
The growing risk of canine diseases is expected to drive growth of the market over the forecast period.
The increasing prevalence of canine diseases in animals is expected to spur the growth of the global veterinary drugs compounding market over the forecast period. For instance, according to the 2019 AHS Heartworm Incidence Survey, five states of the U.S. including Arkansas, Mississippi, Louisiana, South Carolina, and Alabama reported the highest incidence of heartworm infection in dogs in 2019. Hence, such rising burden of canine disease will promote the development of new compounded drugs over the forecast period.
|Base Year:||2020||Market Size in 2021:||US$ 1,179.7 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||5.5%||2028 Value Projection:||US$ 1,713.8 Mn|
Wedgewood Pharmacy, Pace Pharmacy, Tache Pharmacy, The Pet Apothecary, Pet Script, Golden Gate Veterinary Compounding Pharmacy, CareFirst Specialty Pharmacy, Triangle Compounding Pharmacy, Miller’s Pharmacy, and Davis Islands Pharmacy
|Restraints & Challenges:||
Growing awareness regarding the advantages of veterinary compounding for delivery of medication in animals.
Veterinary compounding refers to the science of preparing personalized medication for animals. These are mostly used in case of companion animals such as dogs, cats, and other small animals for providing multiple or specifically formulated medications keeping into account the special needs of the pet. There are several benefits of compounding animal drugs such as:
Restraint- Global Veterinary Drugs Compounding Market
Risk associated with adulterated compounded veterinary drugs is expected to be a major factor hampering the growth of the global veterinary drugs compounding market. For instance, in June 2020, the U.S. Food and Drug Administration warned veterinary doctors that adulterated and misbranded compounded combination drug product containing pyrimethamine and toltrazuril caused adverse events in at least three horses. The testing revealed that the products contained approximately 18 to 21 times higher pyrimethamine than indicated on the labeling.
Global Veterinary Drugs Compounding Market – Regional Analysis
On the basis of region, the global veterinary drugs compounding market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to be the most lucrative region in the veterinary drugs compounding market, owing to increasing product launches by companies based in this region. For instance, in 2018, Wedgewood Pharmacy, a U.S.-based compounding pharmacy, launched compounding Omeprazole IM Injection Suspension, 100mg/ml in a 20ml vial. The medication is compounded under license from Luoda Pharma Pty Ltd, an Australian biopharmaceutical company that focuses on development of animal health products to meet the clinical needs of animals.
Increasing humanization of pets and increasing expenditure on pet health and wellness are expected to drive the growth of the market in the Asia Pacific region. For instance, in 2019, in Australia, more than US$ 2.6 billion was spent on animal health services as per Animal Medicines Australia. This trend is estimated to continue in the near future. The top reasons cited for veterinary visits were general health checkups, pathology & lab tests, vaccinations, illness or injury, X-ray & imaging, hospitalization, and others.
Figure 2: Global Veterinary Drugs Compounding Market Value (US$ Mn), by Region, 2021
Global Veterinary Drugs Compounding Market – Competitive Landscape
Major players operating in the global veterinary drugs compounding market include Wedgewood Pharmacy, Pace Pharmacy, Tache Pharmacy, The Pet Apothecary, Pet Script, Golden Gate Veterinary Compounding Pharmacy, CareFirst Specialty Pharmacy, Triangle Compounding Pharmacy, Miller’s Pharmacy, and Davis Islands Pharmacy.
The compounding medications for animals is generally prepared by pharmacists or veterinarians. The Federal Food, Drug, and Cosmetic Act (FD&C Act) allows compounding of animal drugs when the active ingredient is derived from a finished FDA-approved drug rather than a bulk drug substance. A ‘bulk drug substance’ is a substance used in the manufacturing of a drug that becomes an active ingredient in the drug's finished dosage form.
Market players are focused on product launches or approvals, this could contribute to the growth of the global veterinary drugs compounding market over the forecast period. For instance, in April 2018, Golden Gate Veterinary Compounding Pharmacy, a company focused on producing high quality custom compounds for meeting the needs of both pets and pet owner announced launch of the Topi-Click Micro Pens. Topi-Click Micro transdermal pens are accurate than other transdermal pens and further eliminate user-variability. In addition to being easy to use and extremely accurate, Topi-Click indicates the measure of dose through each administration, so the person knows exactly how much product is used and how much amount is remaining.
Market players are focused on inorganic strategies such as partnerships and agreements with other market players. This is expected to drive the market growth over the forecast period. For instance, in March 2019, Wedgewood Pharmacy, one of the biggest compounding pharmacy in the U.S., entered into a partnership with Vetsource for adding prescribed compounded medications to Vetsource’s Home-Delivery catalog. Vetsource uses mobile-optimized ScriptRight ePrescribing tool for ordering over-the-counter and nutritional medication products.
Market players focused on initiatives and programs related to healthcare nutrition, which is expected to propel the growth of the global veterinary drugs compounding market. For instance, in June 2021, Covetrus, a veterinary medicine pharmacy, announced that it has acquired VCP, a platform in veterinary wellness plan administration that serves around 1,000 veterinary practices, with over 350,000 pets currently benefiting from VCP-enabled wellness plans. Covetrus will be using VCP's technology platform and infrastructure to provide new ways for veterinarians to foster stronger relationships with their pet parent clients and deliver better business and healthcare outcomes.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.